- Home
- APLM vs SMSI Comparison
APLM vs SMSI Comparison
Compare APLM & SMSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- SMSI
- Stock Information
- Founded
- APLM 2016
- SMSI 1982
- Country
- APLM United States
- SMSI United States
- Employees
- APLM N/A
- SMSI N/A
- Industry
- APLM Blank Checks
- SMSI Computer Software: Prepackaged Software
- Sector
- APLM Finance
- SMSI Technology
- Exchange
- APLM Nasdaq
- SMSI Nasdaq
- Market Cap
- APLM 6.9M
- SMSI 16.7M
- IPO Year
- APLM N/A
- SMSI 1995
- Fundamental
- Price
- APLM $5.79
- SMSI $1.14
- Analyst Decision
- APLM
- SMSI Strong Buy
- Analyst Count
- APLM 0
- SMSI 1
- Target Price
- APLM N/A
- SMSI $5.00
- AVG Volume (30 Days)
- APLM 27.3K
- SMSI 216.5K
- Earning Date
- APLM 08-13-2025
- SMSI 07-31-2025
- Dividend Yield
- APLM N/A
- SMSI N/A
- EPS Growth
- APLM N/A
- SMSI N/A
- EPS
- APLM N/A
- SMSI N/A
- Revenue
- APLM $198,000.00
- SMSI $19,378,000.00
- Revenue This Year
- APLM $415.15
- SMSI $10.12
- Revenue Next Year
- APLM N/A
- SMSI $63.12
- P/E Ratio
- APLM N/A
- SMSI N/A
- Revenue Growth
- APLM N/A
- SMSI N/A
- 52 Week Low
- APLM $4.47
- SMSI $0.52
- 52 Week High
- APLM $35.98
- SMSI $2.57
- Technical
- Relative Strength Index (RSI)
- APLM 40.56
- SMSI 65.88
- Support Level
- APLM $5.11
- SMSI $0.82
- Resistance Level
- APLM $6.56
- SMSI $0.95
- Average True Range (ATR)
- APLM 0.52
- SMSI 0.07
- MACD
- APLM -0.11
- SMSI 0.01
- Stochastic Oscillator
- APLM 20.07
- SMSI 83.05
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About SMSI Smith Micro Software Inc.
Smith Micro Software Inc is a provider of software solutions. It develops and markets wireless solutions for wireless service providers, mobile device and chipset manufacturers, and enterprise businesses. Its portfolio includes family safety software solutions to support families in the digital age and creating, sharing, and monetizing rich content, such as visual voice messaging, retail content display optimization and performance analytics on any product set. The company's only reportable segment is Wireless. Wireless segment includes the Family Safety (which includes SafePath), CommSuite, and ViewSpot families of products.